For the quarter ending 2026-03-31, BBNX made $27,626K in revenue. -$22,394K in net income. Net profit margin of -81.06%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 27,626 | 32,121 | 27,253 | 23,238 |
| Cost of sales | 11,189 | 13,177 | 12,134 | 10,735 |
| Gross profit | 16,437 | 18,944 | 15,119 | 12,503 |
| Research and development | 10,356 | 10,131 | 8,195 | 8,873 |
| Sales and marketing | 20,735 | 16,334 | 16,045 | 15,623 |
| General and administrative | 9,617 | 8,603 | 7,922 | 7,879 |
| Total operating expenses | 40,708 | 35,068 | 32,162 | 32,375 |
| Loss from operations | -24,271 | -16,124 | -17,043 | -19,872 |
| Other expense | - | 0 | 1 | -2 |
| Interest income | 2,376 | 2,658 | 2,833 | 3,005 |
| Change in fair value of warrant liabilities | 0 | 0 | 0 | 0 |
| Total other income (expense), net | 2,376 | 2,658 | 2,834 | 3,003 |
| Net loss | -21,895 | -13,466 | -14,209 | -16,869 |
| Unrealized loss on short-term and long-term investments | -499 | 49 | 205 | -91 |
| Comprehensive loss | -22,394 | -13,417 | -14,004 | -16,960 |
| Basic EPS | -0.49 | -0.302 | -0.33 | -0.39 |
| Diluted EPS | -0.49 | -0.302 | -0.33 | -0.39 |
| Basic Average Shares | 44,436,274 | 44,376,777 | 43,634,006 | 43,390,652 |
| Diluted Average Shares | 44,436,274 | 44,376,777 | 43,634,006 | 43,390,652 |
Beta Bionics, Inc. (BBNX)
Beta Bionics, Inc. (BBNX)